Evidence map›Paper›PMID 23241185›Full record

ArticleExpert review of anti-infective therapy2012

Parasites in the brain? The search for sleeping sickness biomarkers.

Richard Burchmore

Abstract readComment
PubMed Publisher
In one paragraph

Article in Expert review of anti-infective therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. NTD Diagnostics for Disease Elimination: A Review.Diagnostics (Basel, Switzerland) · 2020
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Richard BurchmoreInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK. richard.burchmore@glasgow.ac.uk
University of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evaluation of: Tiberti N, Hainard A, Lejon V et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS ONE 7(7), e40909 (2012). Human African trypanosomiasis (HAT) is a fatal parasitic disease that progresses from an early stage (stage 1), where parasites multiply in the hemolymphatic system, to a late stage (stage 2) disease, where parasites have become manifest within the CNS. Patients with stage 1 disease are treated with relatively safe drugs, but stage 2 disease requires treatment with drugs that are very toxic or difficult to administer. Thus, it is important to determine the stage of HAT infection before treating. HAT staging currently involves microscopic examination of cerebrospinal fluid (CSF), looking for the presence of parasites, or for more than five white blood cells per microliter CSF. This article tested the specificity and selectivity of eight potential CSF markers for stage 2 HAT, by analysis of levels in 400 CSF samples from patients diagnosed with stage 1 or stage 2 HAT by WHO protocols. Two of these markers gave results that were comparable with those obtained by conventional diagnosis. The potential for and challenges of developing improved staging for HAT are discussed.

Identifiers

PMID23241185
OpenAlexW2031472529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.